Comprehensive medication guide to Ganciclovir including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
$0 co-pay for IV form billed through medical benefits in hospital/clinic settings; $30–$75 co-pay for Zirgan under pharmacy benefit on Tier 3–4 formularies. Prior authorization may be required for home infusion or transplant prophylaxis.
Estimated Cash Pricing
$100–$120 cash per 500 mg IV vial (generic); as low as $41 with SingleCare. Zirgan ophthalmic gel retails for $500–$570 per tube; as low as $35 with a GoodRx coupon.
Medfinder Findability Score
62/100
Summarize with AI
On this page
Ganciclovir is a synthetic antiviral medication in the nucleoside analogue class — the same family as acyclovir — but with significantly greater activity against cytomegalovirus (CMV). It was first approved by the FDA in 1988-1989 and remains a cornerstone treatment for CMV disease in immunocompromised patients.
Ganciclovir is available in two distinct formulations in the United States: Cytovene-IV — an intravenous injection (500 mg lyophilized powder vial) used to treat and prevent CMV disease in AIDS patients and organ transplant recipients — and Zirgan — an ophthalmic gel (0.15%, 5g tube made by Bausch & Lomb) used to treat herpetic keratitis (herpes simplex eye infections).
Unlike most medications, ganciclovir IV is administered exclusively by healthcare professionals — patients receive it during hospital stays, at outpatient infusion centers, or through home infusion services. It is not a medication that patients self-inject at home. The ophthalmic gel is self-administered by patients at home per their ophthalmologist's instructions.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Ganciclovir works by blocking cytomegalovirus from copying its genetic material (DNA), which prevents the virus from replicating and spreading. The mechanism is elegantly selective: ganciclovir is a synthetic building block that closely resembles guanosine, one of the natural components of DNA.
The key to its selectivity is a CMV-specific enzyme called UL97 — a viral protein kinase that only exists in CMV-infected cells. UL97 phosphorylates (activates) ganciclovir into its active form, ganciclovir triphosphate (GCV-TP), which accumulates inside infected cells at high concentrations. GCV-TP then inhibits the viral DNA polymerase (UL54), preventing CMV DNA replication. Because UL97 is only produced in CMV-infected cells, GCV-TP preferentially concentrates where the virus is actively replicating.
Ganciclovir is virustatic — it controls CMV replication but does not eliminate the virus from the body. This is why treatment must continue as long as the patient remains immunocompromised and at risk for CMV disease. CMV can develop resistance through mutations in UL97 or UL54 genes, which guides the choice of alternative antivirals (foscarnet or cidofovir) in resistant cases.
500 mg — IV injection (lyophilized powder for reconstitution)
Standard IV vial for induction and maintenance dosing in CMV disease
0.15% — ophthalmic gel (5g tube)
Zirgan ophthalmic gel for herpetic keratitis; 1 drop 5x/day until healing, then 3x/day for 7 days
As of early 2026, ganciclovir is not listed in an active FDA drug shortage. However, localized availability challenges are common because ganciclovir is a specialty medication with a narrow patient population and a limited number of manufacturers. The IV form is distributed primarily through hospital purchasing networks, specialty pharmacies, and home infusion companies — not retail chains.
The Zirgan ophthalmic gel is more widely available at retail pharmacies but may require a special order due to its high retail price and low turnover. For most patients, calling ahead is essential. The findability score for ganciclovir reflects these specialty distribution constraints — it scores a 62/100, meaning it is generally accessible through the right channels but requires more effort than common drugs to locate.
If you're having difficulty finding ganciclovir, medfinder calls pharmacies near you to check which ones have it in stock and can fill your prescription, saving hours of phone calls.
Ganciclovir is not a controlled substance, so any licensed prescriber (MD, DO, NP, or PA) can legally write a prescription. However, due to the complexity of the conditions it treats and its serious side effect profile, ganciclovir is almost always prescribed and managed by specialists. New patients typically need a specialist referral to access this medication.
Infectious Disease (ID) Physicians: Primary specialists for CMV disease management in HIV/AIDS and immunocompromised patients
HIV/AIDS Specialists: Manage CMV retinitis and other HIV-related opportunistic infections at HIV clinics
Transplant Physicians and Surgeons: Prescribe ganciclovir for CMV prophylaxis and treatment after solid organ transplantation
Hematologists and Oncologists: Manage CMV in stem cell transplant and bone marrow transplant recipients
Ophthalmologists and Optometrists: Prescribe Zirgan ophthalmic gel for herpetic keratitis; retinal specialists co-manage CMV retinitis
Telehealth availability for ganciclovir prescribing is limited: IV ganciclovir requires in-person administration in a clinical setting, making initial telehealth prescribing impractical. Established patients on stable ganciclovir or valganciclovir regimens may use telehealth for follow-up visits with their infectious disease or transplant provider in some states. For Zirgan, some ophthalmology telehealth platforms may prescribe for established patients, but initial diagnosis requires an in-person slit-lamp examination.
No. Ganciclovir is not a controlled substance and is not scheduled by the DEA. It does not require a special prescription form, and there are no federally mandated refill restrictions based on controlled substance scheduling.
However, ganciclovir carries a boxed warning for serious side effects — including hematologic toxicity, impairment of fertility, fetal toxicity, and carcinogenesis potential — which means it requires careful clinical oversight despite not being controlled. It is almost always managed by infectious disease specialists, transplant physicians, or ophthalmologists rather than primary care providers acting independently.
Ganciclovir IV is associated with a broad range of side effects, particularly related to bone marrow suppression:
Neutropenia (low white blood cell count) — occurs in >20% of patients
Anemia (low red blood cell count)
Thrombocytopenia (low platelet count)
Fever, nausea, vomiting, diarrhea
Headache, fatigue, sweating
Elevated serum creatinine (kidney stress marker)
Pain or phlebitis at the IV injection site
Serious side effects requiring immediate medical attention:
Pancytopenia (dangerously low counts of all blood cell types)
Seizures (especially when co-administered with imipenem-cilastatin)
Severe renal impairment
Confusion, hallucinations, or mental status changes
For Zirgan ophthalmic gel: Blurred vision (60%), eye irritation (20%), punctate keratitis (5%), conjunctival redness (5%). These are generally localized and transient.
Know what you need? Skip the search.
Valganciclovir (Valcyte)
Oral prodrug of ganciclovir; preferred for outpatient CMV treatment and prophylaxis; same mechanism, widely available as generic
Foscarnet (Foscavir)
IV antiviral for ganciclovir-resistant CMV; different mechanism (direct DNA polymerase inhibitor); more nephrotoxic
Letermovir (Prevymis)
CMV prophylaxis in allogeneic stem cell transplant recipients; novel CMV terminase inhibitor; better tolerated than ganciclovir
Cidofovir
IV antiviral for treatment-refractory CMV retinitis; weekly dosing; significant nephrotoxicity requires prehydration
Trifluridine (Viroptic)
Ophthalmic alternative to Zirgan for herpetic keratitis; available as generic; more frequent dosing than Zirgan
Prefer Ganciclovir? We can find it.
Imipenem-cilastatin (Primaxin)
majorCombination associated with generalized seizures; avoid concurrent use unless benefit outweighs risk
Zidovudine (AZT, Retrovir)
majorAdditive myelosuppression — combined use increases risk of severe neutropenia and anemia; many patients cannot tolerate full doses of both
Mycophenolate mofetil (CellCept)
moderateBoth drugs compete for renal tubular secretion and have additive myelosuppressive effects; frequent CBC monitoring required
Didanosine (ddI, Videx)
moderateGanciclovir significantly increases didanosine blood levels; raises risk of pancreatitis and peripheral neuropathy
Tenofovir (TDF/TAF)
moderateGanciclovir may increase tenofovir concentrations via renal transport competition; monitor renal function
Probenecid
moderateReduces renal clearance of ganciclovir, increasing drug levels and toxicity risk; dose adjustment may be needed
Ganciclovir has been protecting some of medicine's most vulnerable patients for over three decades. From CMV retinitis in AIDS patients to post-transplant CMV prophylaxis, it occupies a critical niche in antiviral therapy. Its oral prodrug, valganciclovir, has largely replaced it for outpatient use — but IV ganciclovir remains irreplaceable for hospitalized patients and those who cannot absorb oral medications.
If you are prescribed ganciclovir, the most important things to remember are: take it exactly as prescribed, attend all required blood test appointments, never stop treatment without consulting your doctor, and ensure you have a reliable supply before you need it. Ganciclovir is a specialty medication that requires proactive coordination between patient, provider, and pharmacy.
Finding ganciclovir in stock at a pharmacy near you shouldn't add to the stress of managing a serious illness. medfinder calls pharmacies on your behalf to find which ones have your medication in stock and can fill your prescription — so you can focus on your health.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards